Author:
Mussini Cristina, ,Lorenzini Patrizia,Cozzi-Lepri Alessandro,Marchetti Giulia,Rusconi Stefano,Gori Andrea,Nozza Silvia,Lichtner Miriam,Antinori Andrea,Cossarizza Andrea,d’Arminio Monforte Antonella
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. European AIDS Clinical Society Guidelines 2017.
www.eacsociety.org/files/guidelines_8.2-english.pdf
. Accessed Jan 2017.
2. DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV.
https://aidsinfo.nih.gov/guidelines
. Accessed 27 Mar 2018.
3. Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load <50 HIV-1 RNA copies/mL at baseline. HIV Med. 2012;13:398–405.
4. Valantin MA, Lambert-Niclot S, Flandre P, et al. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother. 2012;67:691–5.
5. Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942–51.
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献